After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma companies,” says founder Alex Zhavoronkov.After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma companies,” says founder Alex Zhavoronkov.
